Fractyl Logo

Fractyl Health to Present Landmark Updates on Revita® and Rejuva® Programs at the 83rd American Diabetes Association

LEXINGTON, Mass.–(BUSINESS WIRE)– Fractyl Health, an organ-editing metabolic therapeutics company pioneering new approaches to prevent and reverse type 2 diabetes (T2D), announced today its participation in the upcoming 83rd Scientific Sessions of the American Diabetes Association, happening June 23-26, 2023, in San Diego, CA, and virtually.

Fractyl Health will present clinical and preclinical updates on its Revita® and Rejuva® programs, respectively. The first presentation, “Glycemic Improvement, Insulin Reductions, and Improved Body Weight 48 Weeks after Revita Duodenal Mucosal Resurfacing in T2D Patients with Previously Inadequately Controlled Glucose Despite Multiple Glucose-Lowering Agents Including Insulin,” will be presented in an ePoster Theater session on Saturday, June 24, 2023, from 12:40 PM – 12:50 PM (Pacific) and during a General Poster Session on Sunday, June 25, 2023, from 11:30 AM – 12:30 PM (Pacific).

The second presentation, “Pancreatic Gene Therapy Durably Improves Glycemia and Delays Disease Progression in a Murine Model of Type 2 Diabetes,” comparing single dose pancreatic gene therapy to chronic administration of semaglutide in a db/db rodent model of Type 2 Diabetes and obesity, will be delivered during an oral abstract session on Saturday, June 24, 2023, from 2:30 PM – 2:45 PM (Pacific) in Ballroom 20D.

“We look forward to presenting our groundbreaking findings at the ADA Scientific Sessions,” said Dr. Harith Rajagopalan, CEO of Fractyl Health. “These updates from our Revita® and Rejuva® programs highlight the transformative potential of our metabolic programs in addressing the root causes of T2D aiming to prevent progression and reverse disease.”

About Fractyl Health

Fractyl Health is focused on pioneering new approaches to the treatment of T2D. Despite advances in treatment over the last 50 years, T2D and obesity continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform T2D treatment from chronic blood glucose management to disease-modifying therapies that target the organ-level root causes of the disease. Fractyl Health is a private organ-editing metabolic therapeutics company based in Lexington, MA. For more information, visit or

About Rejuva®

Fractyl Health’s Rejuva® platform focuses on developing next-generation adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of T2D and obesity. The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use. Rejuva leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas. The program aims to transform the management of metabolic diseases by offering novel, disease-modifying therapies that address the underlying root causes of disease.

About Revita®

Fractyl Health’s lead product candidate, Revita®, is based on the company’s insights surrounding the potential role of the gut in metabolic diseases. Revita is designed to remodel the duodenal lining via hydrothermal ablation (i.e., duodenal mucosal resurfacing) to edit abnormal intestinal nutrient sensing and signaling mechanisms that are a potential root cause of metabolic diseases. Revita has received a CE mark in Europe and, in January 2022, received reimbursement authorization through NUB in Germany. In the United States, Revita is for investigational use only under US law. A pivotal study of Revita in patients with inadequately controlled Type 2 Diabetes despite multiple medicines and insulin, called Revitalize 1, is currently enrolling in the United States and Europe.


Lisa Davidson, Chief Financial Officer, 781.902.8800

Beth Brett, Corporate Communications, 720.656.6544